PMID- 29212082
OWN - NLM
STAT- MEDLINE
DCOM- 20180302
LR  - 20180302
IS  - 1423-0232 (Electronic)
IS  - 0030-2414 (Linking)
VI  - 94
IP  - 3
DP  - 2018
TI  - Risk Factors for Chemotherapy-Related Toxicity and Adverse Events in Elderly Thai 
      Cancer Patients: A Prospective Study.
PG  - 149-160
LID - 10.1159/000485078 [doi]
AB  - OBJECTIVES: To assess factors predisposing to severe chemotherapy-related 
      toxicity and adverse events (AEs) and dose modification in aging cancer patients. 
      METHODS: Cancer patients aged >/=70 years scheduled to receive the first cycle of a 
      new chemotherapy regimen were enrolled. On the day of starting chemotherapy, 
      demographic data, performance status (PS), and geriatric parameters were 
      recorded. AEs and chemotherapy modification were recorded. Quality of life (QOL) 
      was assessed at baseline and 3 months after starting chemotherapy or at the end 
      of chemotherapy. RESULTS: We included 151 patients (mean age, 76.4 years) with 
      gastrointestinal (47%), lung (24%), breast (9%), or genitourinary (6%) cancer. 
      All-grade and severe AEs occurred in 83 and 42% of patients, respectively; 51.6% 
      of patients required chemotherapy modification due to toxicities. A higher 
      incidence of severe AEs (71% vs. 39%, p = 0.01) and poorer QOL was found in 
      patients with PS 2 than in those with PS 0-1. Patients with PS 2 or who received 
      palliative-intent chemotherapy or had multiple comorbidities were more likely to 
      discontinue chemotherapy because of toxicity. CONCLUSIONS: PS remains a key 
      predictor of chemotherapy-related toxicity in elderly patients. PS 2 was 
      correlated with higher incidence of severe AEs, premature treatment 
      discontinuation, and worsening QOL after treatment.
CI  - (c) 2017 S. Karger AG, Basel.
FAU - Phaibulvatanapong, Ekkamol
AU  - Phaibulvatanapong E
AD  - Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj 
      Hospital, Mahidol University, Bangkok, Thailand.
FAU - Srinonprasert, Varalak
AU  - Srinonprasert V
FAU - Ithimakin, Suthinee
AU  - Ithimakin S
LA  - eng
PT  - Journal Article
DEP - 20171207
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*administration & dosage/*adverse effects
MH  - Drug-Related Side Effects and Adverse Reactions/*etiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Neoplasms/*drug therapy
MH  - Prospective Studies
MH  - Quality of Life
MH  - Risk Factors
MH  - Thailand
OTO - NOTNLM
OT  - Chemotherapy-related toxicity
OT  - Geriatric assessment
OT  - Severe adverse events
EDAT- 2017/12/07 06:00
MHDA- 2018/03/03 06:00
CRDT- 2017/12/07 06:00
PHST- 2017/09/15 00:00 [received]
PHST- 2017/11/08 00:00 [accepted]
PHST- 2017/12/07 06:00 [pubmed]
PHST- 2018/03/03 06:00 [medline]
PHST- 2017/12/07 06:00 [entrez]
AID - 000485078 [pii]
AID - 10.1159/000485078 [doi]
PST - ppublish
SO  - Oncology. 2018;94(3):149-160. doi: 10.1159/000485078. Epub 2017 Dec 7.